Herlev, Denmark
Herlev, Denmark

Time filter

Source Type

Patent
Herlev Hospital and Immudex ApS | Date: 2017-04-12

The present invention describes the use of nucleic acid barcodes as specific labels for MHC multimers to determine the antigen responsiveness in biological samples. After cellular selection the barcode sequence will be revealed by sequencing. This technology allows for detection of multiple (potentially >1000) different antigen-specific cells in a single sample. The technology can be used for T-cell epitope mapping, immune-recognition discovery, diagnostics tests and measuring immune reactivity after vaccination or immune-related therapies.


Patent
Herlev Hospital and University of Aarhus | Date: 2012-12-21

The present inventors have shown that electroporation with calcium ions are efficient on cutaneous and subcutaneous nodules. In particular the present inventors here disclose that a solution comprising calcium ions (Ca^(2+)) with a concentration of at least 0.1 M is extremely useful in a method of treating a neoplasm, such as cancer with means for causing transient permeabilisation of the cell membranes of at least part of the neoplasm before, during and/or after administration of said solution, wherein said solution is administered with a ratio of 0.2 to 0.8 of the volume of said part of the neoplasm.


Patent
University of Heidelberg and Herlev Hospital | Date: 2011-12-21

The present invention relates to methods for improving the diagnosis of pancreatic and ampullary adenocarcinomas by making use of specific mi RNA biomarkers and/or mi RNA classifiers.


Patent
Herlev Hospital, University of Heidelberg and Rigshospitalet | Date: 2013-01-16

The present invention relates to methods for improving the diagnosis and prognosis of patients with pancreatic carcinoma by making use of specific miRNA biomarkers associated with pancreatic carcinoma that may be identified based on a blood sample, in particular a whole blood, serum or plasma sample, from an individual.


Jrogensen A.B.,Copenhagen University | Frikke-Schmidt R.,Copenhagen University | Nordestgaard B.G.,Copenhagen University | Nordestgaard B.G.,Herlev Hospital | And 2 more authors.
New England Journal of Medicine | Year: 2014

BACKGROUND: High plasma levels of nonfasting triglycerides are associated with an increased risk of ischemic cardiovascular disease. Whether lifelong low levels of nonfasting triglycerides owing to mutations in the gene encoding apolipoprotein C3 (APOC3) are associated with a reduced risk of ischemic cardiovascular disease in the general population is unknown. METHODS: Using data from 75,725 participants in two general-population studies, we first tested whether low levels of nonfasting triglycerides were associated with reduced risks of ischemic vascular disease and ischemic heart disease. Second, we tested whether loss-of-function mutations in APOC3, which were associated with reduced levels of nonfasting triglycerides, were also associated with reduced risks of ischemic vascular disease and ischemic heart disease. During follow-up, ischemic vascular disease developed in 10,797 participants, and ischemic heart disease developed in 7557 of these 10,797 participants. RESULTS: Participants with nonfasting triglyceride levels of less than 1.00 mmol per liter (90 mg per deciliter) had a significantly lower incidence of cardiovascular disease than those with levels of 4.00 mmol per liter (350 mg per deciliter) or more (hazard ratio for ischemic vascular disease, 0.43; 95% confidence interval [CI], 0.35 to 0.54; hazard ratio for ischemic heart disease, 0.40; 95% CI, 0.31 to 0.52). Heterozygosity for loss-of-function mutations in APOC3, as compared with no APOC3 mutations, was associated with a mean reduction in nonfasting triglyceride levels of 44% (P<0.001). The cumulative incidences of ischemic vascular disease and ischemic heart disease were reduced in heterozygotes as compared with noncarriers of APOC3 mutations (P=0.009 and P=0.05, respectively), with corresponding risk reductions of 41% (hazard ratio, 0.59; 95% CI, 0.41 to 0.86; P=0.007) and 36% (hazard ratio, 0.64; 95% CI, 0.41 to 0.99; P=0.04). CONCLUSIONS: Loss-of-function mutations in APOC3 were associated with low levels of triglycerides and a reduced risk of ischemic cardiovascular disease. Copyright © 2014 Massachusetts Medical Society.


Patent
Glostrup Hospital and Herlev Hospital | Date: 2011-10-21

A method for treating a patient by covering a tissue region with a electric field capable of transiently or permanently permeabilizing cells in said tissue region, comprising the steps of: a. positioning the electrodes of an electrode device in a tissue region to be treated; and b. creating a specific polarity pattern by applying to a first subset of electrodes comprising at least two electrodes a first polarity while at the same time applying to a second subset of electrodes comprising at least two electrodes a second polarity.


The present invention relates to prognostic micro RNA (miRNA) biomarkers based on a specific miRNA expression pattern, which can prove as a valuable prognostic tool to predict the survival of patients being diagnosed with pancreas cancer.


Patent
Herlev Hospital | Date: 2012-10-17

The present invention relates to the field of prophylaxis and therapy of clinical conditions including cancer, autoimmune diseases and infectious diseases. In particular there is provided vaccine compositions comprising PD-L1 or peptide fragments thereof that are capable of eliciting immune responses useful in treatment of cancer, autoimmune diseases or infectious diseases.


The present invention lies within the field of personalised medicine. More particular the invention relates to biomarkers useful for predicting treatment efficacy and prognosis in cancer patients. Thus the invention provides microRNAs (miRNAs) which are useful for predicting efficacy of anti-angiogenic treatment. In particular, miR-664 for the prediction of response to bevacizumab in colorectal cancer of sigmoid colon or rectum.


Rosenberg J.,Herlev Hospital
Danish medical bulletin | Year: 2011

The nationwide Danish Hernia Database, recording more than 10,000 inguinal and 400 femoral hernia repairs annually, provides a unique opportunity to present valid recommendations in the management of Danish patients with groin hernia. The cumulated data have been discussed at biannual meetings and guidelines have been approved by the Danish Surgical Society. Diagnosis of groin hernia is based on clinical examination. Ultrasonography, CT or MRI are rarely needed, while herniography is not recommended. In patients with indicative symptoms of hernia, but no detectable hernia, diagnostic laparoscopy may be an option. Once diagnosed, hernia repair is recommended in the presence of symptoms affecting daily life. In male patients with minimal or absent symptoms watchful waiting is recommended. In females, however, repair is recommended also in asymptomatic patients. In male patients with primary unilateral or bilateral groin hernia the preferred method is mesh repair, either at open surgery (Lichtenstein) or laparoscopically, irrespective of age. Conventional tension-producing methods like Bassini, McVay or Shouldice are no longer recommended in a routine elective setting. Whether repair should be done by open or laparoscopic technique, depends on local expertise, economical considerations and patient preference. Compared to the Lichtenstein operation laparoscopic repair is associated with less acute pain and faster recovery. Furthermore, available data suggest less chronic long-term pain after laparoscopic repair. In female patients laparoscopic repair is the recommended method. In patients with recurrent hernia laparoscopic repair is preferred in patients with a previous open repair, while patients with recurrence after laparoscopic repair should undergo open mesh repair. In open repair it is recommended to use a mesh secured with a nonabsorbable monofilament suture. In laparoscopic repair a mesh without a slit and with a minimum size of 15 by 10 cm is used. For mesh fixation absorbable or nonabsorbable tacks or glue can be used. Elective surgery for groin hernia should be performed in an outpatient setting, using cost-effective local anaesthesia in open mesh repair and general anaesthesia for laparoscopic repair. Spinal anaesthesia is not recommended. Routine prophylactic antibiotics are not indicated. In the early convalescence period there are no physical restrictions. These guidelines will also be available at the website for the Danish Hernia Database (www.herniedatabasen.dk). The guidelines will be updated when new substantial evidence becomes available.

Loading Herlev Hospital collaborators
Loading Herlev Hospital collaborators